Fatigue relief study for primary biliary cholangitis
Part of Digestive system clinical trials.
This trial tests a program of exercise, nutrition, and education to help reduce fatigue in people with primary biliary cholangitis. It aims to see if this program can improve energy and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have been diagnosed with primary biliary cholangitis (PBC)
- You experience moderate to severe fatigue (scoring 29 or more on a PBC fatigue questionnaire)
- You are not on the liver transplant list and have not had a liver transplant
- You do not have severe itching, decompensated cirrhosis, or other serious health conditions listed by the study doctors
- You can participate in a program that includes exercise, diet, and lifestyle changes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This study tracks patients with primary biliary cholangitis (PBC) over time to understand long-term outcomes. It aims to gather information that could improve care and management for people with PBC.
This study uses a smartphone app or digital platform to track how you're feeling day-to-day if you have primary biliary cholangitis (PBC), a liver condition where your immune system damages bile ducts. Researchers want to see if this digital monitoring helps them better understand and manage PBC symptoms.
This trial tests a drug called elafibranor for people with primary biliary cholangitis (PBC), a liver disease. It aims to see if the drug is safe and works well over a long time.
This study tests whether fenofibrate, a medicine that lowers fats in the blood, can help people with primary biliary cholangitis (a chronic liver disease) who haven't had treatment before. It aims to see if it is safe and effective as a first treatment option.
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
Hear when a new Primary Biliary Cholangitis (PBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.